Recon: Gilead’s Trodelvy falters in lung cancer study; EMA weighs cardiovascular indications for Novo’s Wegovy
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States